AstraZeneca Beats Forecasts, Unveils Cost-Savings Drive to Fund Pipeline Growth
AstraZeneca posted solid 9M and Q3 results, beat forecasts, and launched a $1.5bn savings plan to fund its pipeline.
AstraZeneca posted solid 9M and Q3 results, beat forecasts, and launched a $1.5bn savings plan to fund its pipeline.
Summit and AstraZeneca will co-develop ivonescimab combinations, starting with GI cancers. Each company keeps rights to its own medicines.
HARMONi-2: Summit’s Ivonescimab extended median survival by 8.2 months vs Keytruda. 42% lower death risk in PD-L1-high patients.
Analysts see a likely PFS win in HARMONi-3 later in 2026.
HARMONi Phase 3 results in The Lancet Oncology show ivonescimab + chemo cuts progression risk nearly in half for post-TKI EGFR-mutated NSCLC.
Summit Therapeutics says its cash won’t cover operations for a year, raising going-concern concerns. Shares fall as the company seeks funding while advancing ivonescimab development.